RxDoctor Payments Data

Margo Joubran, PA

Medical · Toledo, OHNPI 1144819814

Payments from drug & device makers

$3,010in general payments, 2019–2025

Across 62 payments — averaging $48.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Dexcom, Inc.$342
  • Abbott$312
  • Tandem Diabetes Care, Inc.$216
  • Novo Nordisk$176
  • Insulet Corporation$130
  • plus $172 from 3 others

What the payments were for

  • Travel & lodging$1,11337%
  • Food & beverage$1,89863%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,010 in reported general payments places this provider in the 80th percentile of 547 medical providers in Ohio.

See all medical providers in Ohio

Medicare billing

Part B allowed, 2024
$33,942
Medicare patients
104
Services billed
644

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide164$216,296
MounjaroTirzepatide127$161,883
OzempicSemaglutide120$145,594
JardianceEmpagliflozin70$92,573
FarxigaDapagliflozin Propanediol65$80,630
JanuviaSitagliptin Phosphate48$55,684
Fiasp FlextouchInsulin Aspart (Niacinamide)63$47,804
Humulin R U-500 KwikpenInsulin Regular, Human21$41,375
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$28,897
Tresiba Flextouch U-200Insulin Degludec26$25,033
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog81$24,032
Humalog Kwikpen U-100Insulin Lispro71$24,027
Tresiba Flextouch U-100Insulin Degludec31$22,415
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$22,089
Lantus SolostarInsulin Glargine,hum.Rec.Anlog129$17,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$28$388,069332 claims
Novo NordiskOzempic, Novolog$176$153,689146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 547 medical providers in Ohio.

Other medical in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →